KFAS
KNSA icon

Keating Financial Advisory Services’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Keating Financial Advisory Services’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64 Buy
+1
New +$52 ﹤0.01% 2500

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Keating Financial Advisory Services's KNSA Position: Q2 2026 in Review

Keating Financial Advisory Services opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 1 share worth $64. The stake represents ﹤0.01% of the portfolio and ranks #2500 among its holdings.

266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Keating Financial Advisory Services held 1 share of Kiniksa Pharmaceuticals worth $64 as of Q2 2026.
  • Kiniksa Pharmaceuticals was a new Keating Financial Advisory Services position in Q2 2026.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2500 holding.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.